lulizumab pegol   Click here for help

GtoPdb Ligand ID: 8460

Synonyms: BMS-931699 | BMS931699
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody [3]. PEGylation improves solubility and extends circulating half-life [2].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
1. Howland KC, Ausubel LJ, London CA, Abbas AK. (2000)
The roles of CD28 and CD40 ligand in T cell activation and tolerance.
J Immunol, 164 (9): 4465-70. [PMID:10779746]
2. Pisal DS, Kosloski MP, Balu-Iyer SV. (2010)
Delivery of therapeutic proteins.
J Pharm Sci, 99 (6): 2557-75. [PMID:20049941]
3. Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H et al.. (2013)
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
J Immunol, 191 (9): 4599-610. [PMID:24081989]
4. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. (1989)
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.
Proc Natl Acad Sci USA, 86 (4): 1333-7. [PMID:2465550]